Clinical Trial Detail

NCT ID NCT04195139
Title Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM (NUTMEG)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Sydney
Indications

glioblastoma multiforme

malignant glioma

gliosarcoma

Therapies

Nivolumab + Temozolomide

Temozolomide

Age Groups: senior

No variant requirements are available.